Нимесулид в терапевтической практике

1. Emery P. Considerations for nonsteroidal anti–inflammatory drug therapy: benefits. Scand J Rheumatol 1996; 25 (Suppl 105): 5–12.
2. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.
3. Traversa G, Bianchi C, Da Cas R et al Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
4. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm Res 1997; 46: 437–46.
5. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneim-Forsch/Drug Res 1995; 45: 1093–6.
6. Patrignani P, Panara MR, Sciulli MG et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and 2 by nonsteroidal antiinflammatory drugs. J Physiol Pharmacol 1997; 48: 263–31.
7. Grossman CJ, Wiseman J, Lucas FS et al. Inhibition of constitutive and inducible cyclo–oxygenase activity in human platelets and mononuclear cells by NSAIDs and COX 
2 inhibitors. Inflam Res 1995; 44: 253–7.
8. Patrignani P, Panara MR, Santini G et al. Differential inhibition of the cyclooxygenase activity of prostaglandin endoperoxide synthase isozymes in vitro and ex vivo. 10th International Conference on prostaglandins and Related compounds [abstract] 1996; 115: 22–27.
9. Bianco S, Robuschi M, Gambaro G et al. Bronchial inflammation and NSAIDs Drug Invest 1991; 3 (Suppl. 2): 33–8.
10. Bennett A. Nimesulide a well established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Therapeutic Roles of Selective COX-2 Inhibitors. Editors Vein JR, Botting RM, William Harvey Press: 524–40.
11. Ward A, Brogden RN. Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states Drugs 1988; 36 (6): 732–53.
12. Brune K., Craf P., Non-steroidal antiinflammatory drugs: influence of extra-cellular pH on biodistribution and pharmacological effects. Biochem pharmacol 1978; 27: 525–30.
13. Rainford KD, Schweitzer A, Brune K. Autoradiographic and biochemical observations on the distribution of non-steroidal antiinflammatory drugs. Arch Int pharmacodyn Therap 1991; 250: 180–94.
14. Bjarnason I, Thjodleifsson B. Gastrointestinal toxicity of nonsteroidal anti–inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology 1999; 38 (Suppl. 1): 24–32.
15. Bernareggi A. Pharmacokinetics of nimesulide. Clin Pharm 1998; 35 (4); 247–74.
16. Bernareggi A. The pharmacokinetics profile of nimesulide in healthy volunteers. Drugs 1993; 46 (Suppl. 1); 64–72.
17. Di Battista JA, Fahmi H, He Y et al. Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts. Clin Exp Rheumatol 2001; 19 (Suppl. 22), S3–5.
18. Ward A, Brogden RN. Nimesulide. A preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states Drugs 1988; 36(6): 732–53.
19. Shah AA, Murray FE, Fitzgerald DJ. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology 1999; 38 (Suppl 1): 19–23.
20. Cullen L, Kelley L, Connor SO, Fitzgerald DJ Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharm Exp Ther 1998; 287: 578–82.
21. Tavares IA, Borrelli F, Welsh NJ. Inhibition of gastric acid secretion by nimesulide: a possible factor in its gastric tolerability. Clin Exp Rheumatol 2001; 19 (1 Suppl 22): S13–5.
22. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? TIPS 1999; 20: 4–6.
23. Marini U, Spotti D, Magni E, Monti T. Double-blind endoscopic study comparing the effect of nimesulidi and placebo on gastric mucosa, of dyspeptic subjects. Drug Invest 1990; 2: 162–6.
24. Wober W. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology 1999; 38 (Suppl 1): 33–8.
25. Huskisson EC, Macciocchi A, Rahlfs VW et al. Nimesulide versus diclifenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr Ther Res 1999; 60: 253–65.
26. Porto A, Reis C, Perdigoto R et al. Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis. Curr Ther Res 1998; 59: 654–65.
27. Panara MR, Padovano R, Sciulli M et al. Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clin Pharmacol Ther 1998; 63: 672–81.
28. Warner TD, Guiliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–8.
29. Marbet GA, Yasikoff Strub ML, Macciocchi A, Tsakiris DA. The effect of nimesulide versus placebo on hemostasis in healthy volunteers. Eur J Clin Pharmacol 1998; 54: 383–7.
30. Барскова В.Г., Насонова В.А., Цапина Т.Н. и др. Эффективность и безопасность применения нимесила у больных с подагрическим артритом. Клин. Мед., 2004; 82 (12): 49–54.
31. Мазуров В.И., Лила А.М. Отчет о результатах пилотного исследования по сравнительной оценке влияния найза (нимесулида) и диклофенака на гемодинамические показатели у больных остеоартрозом в сочетании с эссенциальной артериальной гипертензией, кафедра терапии 1 им. Э.Э.Эйхвальда с курсом ревматологии Медицинской академии последипломного образования, Санкт-Петербург, 2007.
32. Huskisson E, Macciocchi A, Rahlfs V еt al. Nimesulid versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr Ther Res 1999; 60: 253–65.
33. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulid and naproxen in patients with osteoarthritis. Int Clin Pract 2001; 55 (8): 510–14.
34. Helin-Salmivaara A, Viranen A, Vesalainen R. еt al. NSAID use the risk of hospatalisation for first myocardial infarction in general population: a national case-control study from Finland. Eur Heart J 2006; 27: 1657–63.
35. Pelletier JP, Di Battista JA, Zhang M et al. Effect of nimesulide on glucocorticoid receptor activity in human synovial fibroblasts. Rheumatology 1999; 38 (Suppl. 1); 11–13.
36. Ferreira SH. The role of interleukins and nitric oxid in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46 (Suppl. 1): 1–9.
37. Bianco S, Robuschi M, Petrigini G et al. Efficacy and tolerability of nimesulidi in asthmatic patients intolerant to aspirin. Drugs 1993; 46 (Suppl 1): 115–20.
38. Pelletier JP, Mineau F, Fernandes JC et al. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 1997; 15: 393–8.
39. Hentrotin YE, Labasse AH, Simonis PE et al. Effects of nimesulide and sodium diclofenac on interleukin–6, interleukin–8, proteoglycans and prostaglandin E2 production by human articular chondrocytes in vitro. Clin Exp Rheumatol 1999; 17:151–60.
40. Barracchini A, Franceschini N, Amicosante G et al. Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. J Pharm Pharmacol 1998; 50: 1417–23.
41. Mukherjee P, Rachita C, Aisen P, Pasinetti GM. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol 2001; 19 (1 Suppl 22): S7–11.
42. Senna GF, Betteli C, Givanni S, Scaricabarozzi I, Andri LG. Antihistaminic activity of nimesulide, a nonsteroidal anti–inflammatory drug. Allergy Clin Immunol 1993; 9 (2): 241.
43. Rossoni G, Berti F, Buschi A, Villa LM, Della Bella D. New data concerning the antianaphylactic and antihistaminic activity of nimesulide. Drugs 1993; 46 (Suppl. 1): 22–8.
44. Dreiser RL. Nimesulidi in the treatment of osteoarthritis of the hip: A dose-finding study. Helsinn, Internal Report 1991.
45. Bourgeois P, Dreiser RL, Lequesne MG et al. Multi-centre double-blind study to define the most favourable dose of Nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheum Inflam 1994; 14: 39–50.
46. Famaey JP, Vanderkerckhove K, Geczy J, Bruhwyler J. A large, open-label trial of nimesulide in patients with osteoarticular conditions treated in a general practice setting. Curr Ther Res 1998; 59: 467–82.
47. Fossaluzza V, Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double–blind trial versus naproxen. J Int Med Res 1989; 17 (3): 295–303.
48. Sarzi-Puttini P, Santadrea S, Boccassini L, Panni B, Caruso I. The role of NSAID in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19 (1 Suppl 22): S17–20.
49. Балабанова Р.М., Белов Б.С., Чичасова Н.В. и др. Эффективность нимесила при ревматоидном артрите. Клин Мед., 2002: 80 (6): 49–52.
50. Барскова В.Г., Якунина И.А., Насонова В.А. Применение нимесила при подагрическом артрите. Тер. арх., 2003; 5: 60–4.
51. Барскова В.Г., Насонова В.А., Цапина Т.Н Эффективность и безопасность применения нимесила при подагрическом артрите, Клин. Мед., 2004; 82 (12): 49–54.
52. Pulkkinen MO. Alterations in intrauterine pressure, menstrual fluid prostaglandin F levels, and pain in dysmenorrheic women treated with ni mesulide. J Clinical Pharmac 1987; 27: 65–9.
53. Lotti T, Mirone V, Imbimbo C et al. Controlled clinical studies if Nimesulid in the treatment of urogenital inflammation. Drugs 1993; 46 (Suppl. 1): 144–6.

В.Г.Барскова 
Учреждение Российской академии медицинских наук НИИ ревматологии, Москва